Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA. · 2017
Read Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. by Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5498998.txt.
Introduction
Berg and co-authors present a resource study in Molecular Cancer on colorectal cancer cell lines. Such cell lines are standard lab models for this cancer. Choosing the right line for a study needs deep molecular detail. The team profiled 34 widely used lines at several levels at once. DNA, RNA, and protein data were all collected.
Deep sequencing covered 612 genes in each line. Copy number, gene activity, small RNA, and 297 proteins were also measured. The lines matched the genomic profiles of real tumors, they report. Two big expression groups emerged, colon-like and undifferentiated. Strong extra copies of oncogenes such as MYC appeared in single lines. The dataset is shared in open formats.
Catalog record
| CREATOR | Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies By Kaja C. G. Berg, Peter W. Eide, Ina A. Eilertsen, Bjarne Johannessen, Jarle Bruun, Stine A. Danielsen, Merete Bjørnslett, Leonardo A. Meza-Zepeda, Mette Eknæs, Guro E. Lind, Ola Myklebost, Rolf I. Skotheim Published in: Molecular Cancer DOI: 10.1186/s12943-017-0691-y ABSTRACT Background Colorectal cancer (CRC) cell lines are widely used pre-clinical model systems. Comprehensive insights into their molecular characteristics may improve model selection for biomedical studies. Methods We have performed DNA, RNA and protein profiling of 34 cell lines, including (i) targeted deep sequencing (n = 612 genes) to detect single nucleotide variants and insertions/deletions; (ii) high resolution DNA copy number profiling; (iii) gene expression profiling at exon resolution; (iv) small RNA expression profiling by deep sequencing; and (v) protein expression analysis (n = 297 proteins) by reverse phase protein microarrays. Results The cell lines were stratified according to the key molecular subtypes of CRC and data were integrated at two or more levels by computational analyses. We confirm that the frequencies and patterns of DNA aberrations are associated with genomic instability phenotypes and that the cell lines recapitulate the genomic profiles of primary carcinomas. Intrinsic expression subgroups are distinct from genomic subtypes, but consistent at the gene-, microRNA- and protein-level and dominated by two distinct clusters; colon-like cell lines characterized by expression of gastro-intestinal differentiation markers and undifferentiated cell lines showing upregulation of epithelial-mesenchymal transition and TGFβ signatures. This sample split was concordant with the gene expression-based consensus molecular subtypes of primary tumors. Approximately ¼ of the genes had consistent regulation at the DNA copy number and gene expression level, while expression of gene-protein pairs in general was strongly correlated. Consistent high-level DNA copy number amplification and outlier gene- and protein- expression was found for several oncogenes in individual cell lines, including MYC and ERBB2. Conclusions This study expands the view of CRC cell lines as accurate molecular models of primary carcinomas, and we present integrated multi-level molecular data of 34 widely used cell lines in easily accessible formats, providing a resource for preclinical studies in CRC. Electronic supplementary material The online version of this article (doi:10.1186/s12943-017-0691-y) contains supplementary material, which is available to authorized users. BACKGROUND Colorectal cancers (CRC) are molecularly heterogeneous and can be divided into clinically relevant subtypes associated with patient prognosis and treatment response. At the DNA level, this includes the genomic instability phenotypes microsatellite instability (MSI) and chromosomal instability (CIN), as well as the epigenomic CpG island methylator phenotype (CIMP). About 15% of primary CRCs have MSI, while the rest are microsatellite stable (MSS), most of which have the CIN phenotype. MSI tumors have errors in the mismatch repair machinery and display numerous single nucleotide variants (SNVs) and insertions/deletions (indels) [1]. CIN tumors typically display aneuploidy with structural and/or numerical aberrations, but the underlying cause(s) remains undetermined [2]. CIMP tumors overlap to a large extent with MSI and are characterized by widespread hypermethylation of CpG islands [3, 4]. At the transcriptional level, several classification schemes have identified biologically distinct subtypes of CRCs [5–7]. The recent identification of four consensus molecular subtypes (CMS) has provided evidence that the expression subtypes have clinical relevance independent of cancer stage [8]. Although several genomic aberrations associate with individual CMS groups, including MSI and hypermutation in CMS1 and oncogene amplification in CMS2, a potential genomic basis for the expression subtypes remains elusive. Integrative DNA, RNA and protein level analyses promise to improve our understanding of the biological and clinical importance of the evolving molecular classification of CRC. CMS classification is heavily influenced by the tumor microenvironment, as demonstrated by strong expression of mesenchymal marker genes in the stroma of tumors of the stem-like/mesenchymal subtype CMS4 [9, 10]. However, all four CMS subtypes were recently demonstrated to be represented in in vitro model systems (Sveen et al., submitted), and cancer cell lines may therefore be used to identify the cancer cell intrinsic aberrations characteristic of the four CMS groups. Furthermore, genomic studies and drug sensitivity screening have demonstrated that CRC cell lines in general recapitulate the molecular alterations and pharmacogenomics of primary tumors [11–15]. Accordingly, improved molecular characterization of these in vitro model systems may further increase their value as preclinical models of CRC. Here we present a resource of information for 34 CRC cell lines by multi-level data integration, including targeted deep sequencing, DNA copy numbers, gene expression, microRNA (miRNA) expression and protein expression. We describe consistent gene/pathway regulation across data types and associate this with known CRC subtypes. Each data set and data combination are presented in accessible tables and figures, emphasizing specific alterations of biological or clinical interest for further experimental studies. METHODS Cell lines – Culturing, processing and analyses overview Thirty-four CRC cell lines purchased from cell line repositories or kindly provided by collaborators (Additional file 1: Table S1), were subjected to DNA, RNA and protein analyses (Fig. 1 a and b). Cell lines were cultured as previously described [12] and harvested at approximately 80–90% confluency. Genomic DNA was extracted either by a standard phenol/chloroform procedure or a magnetic beads protocol (Maxwell 16 DNA purification kit, Promega, Madison, WI, U.S.A.). Cell line authenticity was verified by DNA profiling based on 15 short tandem repeat (STR) loci, using the AmpFLSTR Identifiler PCR Amplification Kit (Thermo Fisher, Waltham, MA) and matched to the profiles from supplier (Additional file 1: Table S1) where available. MSI and CIMP status was determined according to previously described procedures [12]. For CL-40 MSI status was additionally assessed using the MSI Analysis System, version 1.2 (Promega, Fitchburg, WI, USA). Total RNA was extracted using the Qiagen AllPrep DNA/RNA/miRNA Universal kit (Qiagen, Hilden, Germany) and quality controlled by the Agilent RNA 6000 nano kit for Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, U.S.A.). All RIN values were above 9. Protein lysates were produced from cell pellets at the MD Anderson Cancer Centre RPPA Core Facility.Fig. 1Overview of the 34 CRC cell lines analyzed and key findings. a The cell lines are grouped according to the gene expression-based CMSs (except Colo320, which has a neuroendocrine origin), and MSI, POLE and CIMP status are indicated. In general, the morphologic appearance of cell lines in CMS1 and CMS4 (for example LoVo and RKO) was mesenchymal, whereas cell lines in CMS2 and CMS3 (for example IS3 and WiDr) appeared more epithelial-like. b The cell lines were analyzed on the DNA, RNA and protein levels as indicated (blue background). Bioinformatic analyses (grey) were performed both on individual data levels and by integration of two or more data levels. Key findings (white) and references to figures and tables with detailed results are given (green). CIMP: CpG island methylator phenotype, CMS: consensus molecular subtypes, CNA: copy number aberrations, MSI/MSS: microsatellite instable/stable, OG: oncogene, TF: transcription factor, TS: tumor suppressor, SNV: single nucleotide variant For all cell lines, DNA copy number, mRNA, miRNA and protein expression profiles were generated. Targeted DNA sequencing was performed for 27 cancer cell lines in addition to Sanger sequencing of selected genes in 31 cell lines. For frequency counts and statistical tests we excluded the neuroendocrine Colo320 and kept only one cell line derived from the same patient, thus excluding IS3, SW620, DLD-1 and WiDr. Targeted